

DAFTAR PUSTAKA

1. Kemenkes RI. Infodatin-cancer burden 2019. Jakarta Minist Heal RI. 2019;3–6.
2. Kemenkes RI. Profil Kes Indo 2019 [Internet]. Kementerian Kesehatan Republik Indonesia. 2020. 487 p. Available from: <https://pusdatin.kemkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/Profil-Kesehatan-indonesia-2019.pdf>
3. Boyle P, Levin B. World CanCer report 2020 [Internet]. Vol. 199, Cancer Control. France: International Agency for Research on Cancer; 2020. 512 p. Available from: <http://publications.iarc.fr/586>
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–49.
5. Gaona-Luviano P, Adriana L, Medina-Gaona, Magaña-Pérez K. Epidemiology of ovarian cancer. *Chinese Clin Oncol.* 2020;9(4).
6. Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. *Front Immunol.* 2019;10(August):1782.
7. Jasen P. From the “silent killer” to the “whispering disease”: Ovarian cancer and the uses of metaphor. *Med Hist.* 2009;53(4):489–512.
8. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. *Int J Gynecol Obstet.* 2021;155(S1):61–85.
9. Gajjar K, Ogden G, Mujahid MI, Razvi K. Symptoms and Risk Factors of Ovarian Cancer: A Survey in Primary Care. *ISRN Obstet Gynecol.* 2012;2012:1–6.
10. Bast RC, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, et al. Biomarkers and strategies for early detection of ovarian cancer. *Cancer Epidemiol Biomarkers Prev* [Internet]. 2020 Dec 1 [cited 2022 Oct 4];29(12):2504–12. Available from:

<https://aacrjournals.org/cebp/article/29/12/2504/72126/Biomarkers-and-Strategies-for-Early-Detection-of>

11. Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. *J Natl Compr Canc Netw*. 2022;20(9):972–80.
12. Butala AA, Patel RR, Manjunath S, Latif NA, Haggerty AF, Jones JA, et al. Palliative Radiation Therapy for Metastatic, Persistent, or Recurrent Epithelial Ovarian Cancer: Efficacy in the Era of Modern Technology and Targeted Agents. *Adv Radiat Oncol*. 2021 Jan 1;6(1).
13. Patel SC, Frandsen J, Bhatia S, Gaffney D. Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometrioid ovarian cancer: The SEER experience from 2004 to 2011. *J Gynecol Oncol*. 2016;27(5):1–9.
14. Rai B, Bansal A, Patel FD, Sharma SC. Radiotherapy for ovarian cancers - redefining the role. Vol. 15, *Asian Pacific Journal of Cancer Prevention*. 2014. p. 4759–63.
15. Baumann M, Ebert N, Kurth I, Bacchus C, Overgaard J. What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond. *Mol Oncol*. 2020;14(7):1577–85.
16. Albuquerque K V, Singla R, Potkul RK, Smith DM, Creech S, Lo S, et al. Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer. *Gynecol Oncol* [Internet]. 2005 Mar 1;96(3):701–4. Available from: <https://doi.org/10.1016/j.ygyno.2004.11.008>
17. Machida S, Takei Y, Yoshida C, Takahashi Y, Koyanagi T, Sato N, et al. Radiation Therapy for Chemotherapy-Resistant Recurrent Epithelial Ovarian Cancer. *Dep Med Oncol Dana-Farber Cancer Inst* [Internet]. 2014;86(4):232–8. Available from: <https://www.karger.com/DOI/10.1159/000357269>
18. Paulsen F, Waschke J. *Sobotta Atlas of Anatomy, Vol. 2, 16th ed., English/Latin: Internal Organs*. Elsevier Health Sciences Germany; 2018. Available from: <https://books.google.co.id/books?id=SCWPDwAAQBAJ>
19. Snell RS. *Clinical Anatomy by Regions* [Internet]. Lippincott Williams &

Wilkins; 2011. Available from:
<https://books.google.co.id/books?id=vb4AcUL4CE0C>

20. Ravindran, F., Choudhary, B. . Ovarian Cancer: Molecular Classification and Targeted Therapy. In: Ho, G. , Webber, K. , editors. Ovarian Cancer-Updates in Tumour Biology and Therapeutics [Internet]. London: IntechOpen; 2021 [cited 2022 Dec 13]. Available from: <https://www.intechopen.com/chapters/75017> doi: 10.5772/intechopen.95967
21. Terry KL, Missmer SA. Epidemiology of Ovarian and Endometrial Cancers BT - Pathology and Epidemiology of Cancer. In: Loda M, Mucci LA, Mittelstadt ML, Van Hemelrijck M, Cotter MB, editors. Pathology and Epidemiology of Cancer. Cham: Springer International Publishing; 2017. p. 233–46. Available from: https://doi.org/10.1007/978-3-319-35153-7_13
22. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Vol. 11, International Journal of Women's Health. Dove Medical Press Ltd; 2019. p. 287–99.
23. KB K, JL H, DR B, KA P, TM M, MJ RB, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA [Internet]. 2017 Jun 20 [cited 2022 Oct 3];317(23):2402–16. Available from: <https://pubmed.ncbi.nlm.nih.gov/28632866/>
24. Schildkraut JM, Peres LC, Bethea TN, Camacho F, Chyn D, Cloyd EK, et al. Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women. Cancer Causes Control [Internet]. 2019 Sep 1 [cited 2022 Oct 3];30(9):967–78. Available from: <https://pubmed.ncbi.nlm.nih.gov/31236792/>
25. Grimbizis GF, Tarlatzis BC. The use of hormonal contraception and its protective role against endometrial and ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2010 Feb;24(1):29–38.
26. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol [Internet]. 2017 Jun 1 [cited 2022 Oct 3];216(6):580.e1-580.e9. Available from: <https://pubmed.ncbi.nlm.nih.gov/28188769/>

27. Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. *Int J cancer*. 2013 Jun;132(12):2894–900.
28. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. *Am J Surg Pathol* [Internet]. 2010 Mar [cited 2022 Sep 22];34(3):433–43. Available from: <https://pubmed.ncbi.nlm.nih.gov/20154587/>
29. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. *Biomed Res Int*. 2014 [cited 2022 Sep 22];2014. Available from: <https://pubmed.ncbi.nlm.nih.gov/24868556/>
30. Visvanathan K, Gross AL, Kurman RJ, Vang R, Shih IM. Precursor lesions of high-grade serous ovarian carcinoma: Morphological and molecular characteristics. *J Oncol*. 2010;
31. Erickson BK, Conner MG, Landen CN. The role of the fallopian tube in the origin of ovarian cancer. *Am J Obstet Gynecol*. 2013 [cited 2022 Sep 22];209(5):409–14. Available from: <https://pubmed.ncbi.nlm.nih.gov/23583217/>
32. Ebell MH, Culp MB, Radke TJ. A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer. *Am J Prev Med*. 2016 Mar;50(3):384–94.
33. Cannistra SA, Gershenson DM, Recht A. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In 2015.
34. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. *JAMA*. 2004 Jun;291(22):2705–12.
35. Guedea F. Perspectives of brachytherapy: patterns of care, new technologies, and “new biology”. *Cancer Radiother J la Soc Fr Radiother Oncol*. 2014 Oct;18(5–6):434–6.
36. Yossi S, Nguyen D, Khodri M, Reure J, Cervellera M, Lamberth F, et al. [Radiotherapy for ovarian carcinoma management: Literature review]. *Cancer Radiother J la Soc Fr Radiother Oncol*. 2020 Apr;24(2):159–65.
37. Orth M, Lauber K, Niyazi M, Friedl AA, Li M, Maihöfer C, et al. Current concepts in clinical radiation oncology. *Radiat Environ Biophys*. 2014 Mar;53(1):1–29.

38. Bovi JA, White J. Radiation therapy in the prevention of brain metastases. *Curr Oncol Rep*. 2012 Feb;14(1):55–62.
39. Rödel C, Trojan J, Bechstein WO, Woeste G. Neoadjuvant short- or long- term radio(chemo)therapy for rectal cancer: how and who should be treated? *Dig Dis*. 2012;30 Suppl 2:102–8.
40. Zhuang H, Zhao X, Zhao L, Chang JY, Wang P. Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non- small-cell lung cancer. *Drug Des Devel Ther*. 2014;8:667–75.
41. Bhandare N. A Literature Review of Late Complications of Radiation Therapy for Head and Neck Cancers: Incidence and Dose Response. *J Nucl Med Radiat Ther*. 2013 Jan 1;
42. Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. *J Exp Clin Cancer Res*. 2011 Sep;30(1):87.
43. Colhado Rodrigues BL, Lallo MA, Perez EC. The Controversial Role of Autophagy in Tumor Development: A Systematic Review. *Immunol Invest*. 2020 May;49(4):386–96.
44. Proskuryakov SY, Gabai VL. Mechanisms of tumor cell necrosis. *Curr Pharm Des*. 2010 Jan;16(1):56–68.
45. Caruso RA, Branca G, Fedele F, Irato E, Finocchiaro G, Parisi A, et al. Mechanisms of coagulative necrosis in malignant epithelial tumors (Review). *Oncol Lett*. 2014 Oct;8(4):1397–402.
46. Campisi J. Aging, cellular senescence, and cancer. *Annu Rev Physiol*. 2013;75:685–705.
47. Chan KS, Koh CG, Li HY. Mitosis-targeted anti-cancer therapies: where they stand. *Cell Death Dis*. 2012 Oct;3(10):e411.
48. Brown AP, Jhingran A, Klopp AH, Schmeler KM, Ramirez PT, Eifel PJ. Involved-field radiation therapy for locoregionally recurrent ovarian cancer. *Gynecol Oncol*. 2013 Aug;130(2):300–5.
49. Corn BW, Lanciano RM, Boente M, Hunter WM, Ladazack J, Ozols RF. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. *Cancer*. 1994 Dec;74(11):2979–83.

50. E C, Quon M, Gallant V, Samant R. Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer. *Gynecol Oncol*. 2006 Aug;102(2):204–9.
51. De Meerleer G, Vandecasteele K, Ost P, Delrue L, Denys H, Makar A, et al. Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience. *Int J Radiat Oncol Biol Phys*. 2011 Mar;79(3):775–81.
52. Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, et al. A step by step guide for conducting a systematic review and meta-analysis with simulation data. *Trop Med Health*. 2019;47:46.
53. Wang Y, Liu X, Yan P, Bi Y, Liu Y, Zhang ZJ. No Effect of Metformin on Ovarian Cancer Survival: A Systematic Review and Meta-Analysis of Cohort Studies. *Curr Pharm Des*. 2019;25(23):2595–601.
54. Kengsakul M, Nieuwenhuyzen-de Boer GM, Bijleveld AHJ, Udomkarnjananun S, Kerr SJ, Niehot CD, et al. Survival in Advanced- Stage Epithelial Ovarian Cancer Patients with Cardiophrenic Lymphadenopathy Who Underwent Cytoreductive Surgery: A Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2021 Oct;13(19).
55. Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. *Eur J Cancer*. 2020 Mar;127:76–95.
56. Thusgaard CF, Korsholm M, Koldby KM, Kruse TA, Thomassen M, Jochumsen KM. Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review. *Gynecol Oncol*. 2021 Jun;161(3):884–95.
57. Siddiqui MK, Tyczynski J, Pahwa A, Fernandes AW. Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer. *Gynecol Oncol*. 2017 Jul;146(1):44–51.
58. Cianci S, Riemma G, Ronsini C, De Franciscis P, Torella M, Schiattarella A, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer recurrence: systematic review and meta-analysis. *Gland Surg*. 2020 Aug;9(4):1140–8.
59. Kim SI, Cho J, Lee EJ, Park S, Park SJ, Seol A, et al. Selection of patients with

ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2019 Dec;98(50):e18355.

60. Bonte AS, Luyckx A, Wyckmans L, Trinh XB, van Dam PA. Quality indicators for the management of endometrial, cervical and ovarian cancer. *Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol*. 2019 Apr;45(4):528–37.
61. Shi J, Liu B, Wang H, Zhang T, Yang L. Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis. *Int J Gynecol cancer Off J Int Gynecol Cancer Soc*. 2019 Jan;29(1):140–6.
62. Gao S, Zhang W, Yan N, Li M, Mu X, Yin H, et al. The impact of STAT3 and phospho-STAT3 expression on the prognosis and clinicopathology of ovarian cancer: a systematic review and meta-analysis. *J Ovarian Res*. 2021 Nov;14(1):164.
63. Pergialiotis V, Daskalakis G, Thomakos N, Bellos I, Haidopoulos D, Loutradis D, et al. Prechemotherapy Hemoglobin Levels as a Predictive Factor of Ovarian Cancer Survival: A Systematic Review and Meta- Analysis. *Am J Clin Oncol*. 2019 Sep;42(9):725–31.
64. Zhang D, Zhao Y, Wang T, Xi Y, Li N, Huang H. Diabetes mellitus and long-term mortality of ovarian cancer patients. A systematic review and meta-analysis of 12 cohort studies. *Diabetes Metab Res Rev*. 2017 May;33(4).
65. Liu S, Kasherman L, Fazelzad R, Wang L, Bouchard-Fortier G, Lheureux S, et al. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis. *Gynecol Oncol*. 2021 May;161(2):601–12.
66. Nahshon C, Barnett-Griness O, Segev Y, Schmidt M, Ostrovsky L, Lavie O. Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis. *Int J Gynecol cancer Off J Int Gynecol Cancer Soc*. 2022 Jan;32(1):48–54.
67. Yeganeh L, Harrison C, Vincent AJ, Teede H, Boyle JA. Effects of lifestyle modification on cancer recurrence, overall survival and quality of life in gynaecological cancer survivors: A systematic review and meta- analysis. *Maturitas*. 2018 May;111:82–9.
68. Wang R, Sun Q, Wang F, Liu Y, Li X, Chen T, et al. Efficacy and Safety of

Chinese Herbal Medicine on Ovarian Cancer After Reduction Surgery and Adjuvant Chemotherapy: A Systematic Review and Meta-Analysis. Vol. 9, *Frontiers in oncology*. 2019. p. 730.

69. Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. *Gynecol Oncol*. 2015 Nov;139(2):355–62.
70. Rinninella E, Fagotti A, Cintoni M, Raoul P, Scaletta G, Scambia G, et al. Skeletal muscle mass as a prognostic indicator of outcomes in ovarian cancer: a systematic review and meta-analysis. *Int J Gynecol cancer Off J Int Gynecol Cancer Soc*. 2020 May;30(5):654–63.
71. Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Tommasi S, et al. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. *Gynecol Oncol*. 2020 Feb;156(2):377–86.
72. Liu L, Xiong W. Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2021 Aug;100(32):e26849.
73. Dioun S, Wu J, Chen L, Kaplan S, Huang Y, Melamed A, et al. Intraoperative Rupture of the Ovarian Capsule in Early-Stage Ovarian Cancer: A Meta-analysis. *Obstet Gynecol*. 2021 Aug;138(2):261–71.
74. Yu L, Deng L, Li J, Zhang Y, Hu L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. *Gynecol Oncol*. 2013 Feb;128(2):391–6.
75. Di Donato V, Kontopantelis E, Aletti G, Casorelli A, Piacenti I, Bogani G, et al. Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies. *Ann Surg Oncol*. 2017 Jun;24(6):1688–97.
76. Kaneko M. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis. *Ann Pharmacother*. 2022 Jan;56(1):27–34.
77. Lu Y, Li L. The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis. *Technol Cancer Res Treat*. 2021;20:15330338211043784.

78. Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Effects of CytoReductive surgery plus hyperthermic IntraPERitoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis. *Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol*. 2019 Mar;45(3):301–9.
79. Kireeva GS, Gafton GI, Guseynov KD, Senchik KY, Belyaeva OA, Bepalov VG, et al. HIPEC in patients with primary advanced ovarian cancer: Is there a role? A systematic review of short- and long-term outcomes. *Surg Oncol*. 2018 Jun;27(2):251–8.
80. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A. Interval debulking surgery for advanced epithelial ovarian cancer. *Cochrane database Syst Rev*. 2016 Jan;2016(1):CD006014.
81. Cai L, Song Y, Zhao X. Prognostic significance of lymphocyte monocyte ratio in patients with ovarian cancer. *Medicine (Baltimore)*. 2020 Apr;99(14):e19638.
82. Sørensen RD, Schnack TH, Karlsen MA, Høgdall CK. Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities - a systematic review. *Gynecol Oncol*. 2015 Mar;136(3):571–81.
83. Kodama M, Moeini A, Machida H, Blake EA, Grubbs BH, Matsuo K. Feto-maternal outcomes of pregnancy complicated by Krukenberg tumor: a systematic review of literature. *Arch Gynecol Obstet*. 2016 Sep;294(3):589–98.
84. Co M, Liu T, Leung J, Li CH, Tse T, Wong M, et al. Breast Conserving Surgery for BRCA Mutation Carriers-A Systematic Review. *Clin Breast Cancer*. 2020 Jun;20(3):e244–50.
85. Psomiadou V, Prodromidou A, Fotiou A, Lekka S, Iavazzo C. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review. *J Robot Surg*. 2021 Apr;15(2):155–63.
86. Blake EA, Kodama M, Yunokawa M, Ross MS, Ueda Y, Grubbs BH, et al. Feto-maternal outcomes of pregnancy complicated by epithelial ovarian cancer: a systematic review of literature. *Eur J Obstet Gynecol Reprod Biol*. 2015 Mar;186:97–105.
87. Salamanna F, Perrone AM, Contartese D, Borsari V, Gasbarrini A, Terzi S, et al. Clinical Characteristics, Treatment Modalities, and Potential Contributing and

Prognostic Factors in Patients with Bone Metastases from Gynecological Cancers: A Systematic Review. *Diagnostics (Basel, Switzerland)*. 2021 Sep;11(9).

88. Ethier JL, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. *Gynecol Oncol*. 2017 Jun;145(3):584–94.
89. Chellappan DK, Leng KH, Jia LJ, Aziz NABA, Hoong WC, Qian YC, et al. The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review. *Biomed Pharmacother*. 2018 Jun;102:1127–44.
90. Phillips-Chavez C, Watson M, Coward J, Schloss J. A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients. *Eur J Clin Pharmacol*. 2020 Aug;76(8):1059–74.
91. Kodama M, Grubbs BH, Blake EA, Cahoon SS, Murakami R, Kimura T, et al. Feto-maternal outcomes of pregnancy complicated by ovarian malignant germ cell tumor: a systematic review of literature. *Eur J Obstet Gynecol Reprod Biol*. 2014 Oct;181:145–56.
92. van Lieshout LAM, Steenbeek MP, De Hullu JA, Vos MC, Houterman S, Wilkinson J, et al. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. *Cochrane database Syst Rev*. 2019 Aug;8(8):CD012858.
93. Lu Y, Yao DS, Xu JH. Systematic review of laparoscopic comprehensive staging surgery in early stage ovarian cancer: a meta-analysis. *Taiwan J Obstet Gynecol*. 2015 Feb;54(1):29–38.
94. Morano WF, Khalili M, Chi DS, Bowne WB, Esquivel J. Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions-A systematic review. *J Surg Oncol*. 2018 Feb;117(2):245–59.
95. Zhou H, Wu W, Tang X, Zhou J, Shen Y. Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2017 Jan;96(1):e5532.

96. Wang Q, Feng X, Liu X, Zhu S. Prognostic Value of Elevated Pre- treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis. Vol. 12, *Frontiers in oncology*. 2022. p. 868061.
97. Wang TS, Lei W, Cui W, Wen P, Guo HF, Ding SG, et al. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. *Indian J Cancer*. 2014 Mar;51 Suppl 3:e95-8.
98. Prodromidou A, Theofanakis C, Thomakos N, Haidopoulos D, Rodolakis A. Fertility sparing surgery for early-stage clear cell carcinoma of the ovary; A systematic review and analysis of obstetric outcomes. *Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol*. 2021 Jun;47(6):1286– 91.
99. Alavi S, Eckes L, Kratschell R, Taube ET, Rosseck F, Wieners G, et al. Pleomorphic Rhabdomyosarcoma of the Uterus - Case Report and a Systematic Review of the Literature. *Anticancer Res*. 2017 May;37(5):2509–14.
100. Mousavi A, Karimi-Zarchi M, Behtash N, Modares-Gilani M, Mokhtari- Gorgani M, Mehrdad N, et al. The Role of Intraperitoneal Carboplatin as Consolidation Chemotherapy in Women with Ovarian Carcinoma: Report of Our Experience and Systematic Review. *Int J Biomed Sci*. 2016 Dec;12(4):120–4.
101. Xu L, Zhang Y, Tang J, Wang P, Li L, Yan X, et al. The Prognostic Value and Regulatory Mechanisms of microRNA-145 in Various Tumors: A Systematic Review and Meta-analysis of 50 Studies. *Cancer Epidemiol biomarkers Prev a Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol*. 2019 May;28(5):867–81.
102. Xu L, He F, Wang H, Gao B, Wu H, Zhao S. A high plasma D-dimer level predicts poor prognosis in gynecological tumors in East Asia area: a systematic review and meta-analysis. *Oncotarget*. 2017 Aug;8(31):51551– 8.
103. Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Gherzi D, et al. Platinum-containing regimens for metastatic breast cancer. *Cochrane Database Syst Rev* [Internet]. 2017;(6). Available from: <http://dx.doi.org/10.1002/14651858.CD003374.pub4>
104. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. *Cochrane Database Syst Rev* [Internet]. 2000;(1). Available from: <http://dx.doi.org/10.1002/14651858.CD001219>

105. Shylasree TS, Bryant A, Athavale R. Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. *Cochrane Database Syst Rev* [Internet]. 2013;(2). Available from: <http://dx.doi.org/10.1002/14651858.CD006246.pub2>
106. Gurumurthy M, Bryant A, Shanbhag S. Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary (primary and recurrent). *Cochrane database Syst Rev*. 2014 Apr;2014(4):CD006912.
107. Shao Y, Kong J, Xu H, Wu X, Cao Y, Li W, et al. OPCML Methylation and the Risk of Ovarian Cancer: A Meta and Bioinformatics Analysis. Vol. 9, *Frontiers in cell and developmental biology*. 2021. p. 570898.
108. Miniati M, Conversano C, Palagini L, Buccianelli B, Fabrini M, Mancino M, et al. Bipolar Disorder Treatments and Ovarian Cancer: A Systematic Review. *Clin neuropsychiatry*. 2020 Oct;17(5):300–13.
109. Psomiadou V, Gkegkes ID, Iavazzo C. Dermatomyositis and/or polymyositis as a paraneoplastic manifestation of ovarian cancer: a systematic review. *Contemp Oncol (Poznan, Poland)*. 2020;24(4):252–7.
110. Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, et al. Maintenance chemotherapy for ovarian cancer. *Cochrane database Syst Rev*. 2013 Jun;2013(6):CD007414.
111. Liang X, Zeng H, Chen S, Jiang M, Liu S, Fan J. Ovarian metastasis risk factors in endometrial carcinoma: A systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol*. 2021 Dec;267:245–55.
112. Zhu X, Lang J. The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review. *Gynecol Oncol*. 2016 Jul;142(1):184–9.
113. Rombouts AJM, Hugen N, van Beek JJP, Poortmans PMP, de Wilt JHW, Nagtegaal ID. Does pelvic radiation increase rectal cancer incidence? - A systematic review and meta-analysis. *Cancer Treat Rev*. 2018 Jul;68:136– 44.
114. Zhang BL, He N, Huang YB, Song FJ, Chen KX. ABO blood groups and risk of cancer: a systematic review and meta-analysis. *Asian Pac J Cancer Prev*. 2014;15(11):4643–50.
115. Marchetti C, Fagotti A, Tombolini V, Scambia G, De Felice F. The Role of

- Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis. *Ann Surg Oncol*. 2021 Jun;28(6):3258–63.
116. Marchetti C, De Felice F, Perniola G, Palaia I, Musella A, Di Donato V, et al. Role of intraperitoneal chemotherapy in ovarian cancer in the platinum- taxane-based era: A meta-analysis. *Crit Rev Oncol Hematol*. 2019 Apr;136:64–9.
117. Marchetti C, De Felice F, Perniola G, Lecce F, Vertechy L, Monti M, et al. Screening program in ovarian cancer: A logical step in clinical management? A meta-analysis. *Curr Probl Cancer*. 2018;42(2):235–40.
118. Wang JF, Zhao LB, Bin Y di, Zhang KL, Sun C, Wang YR, et al. Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis. Vol. 12, *Frontiers in oncology*. 2022. p. 796983.
119. Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. *ESMO open*. 2022 Sep;7(5):100586.
120. Turner M, Murchie P, Derby S, Ong AY, Walji L, McLernon D, et al. Is stroke incidence increased in survivors of adult cancers? A systematic review and meta-analysis. *J Cancer Surviv*. 2021 Nov;
121. Zhang DF, Dou PH, Zhao DX, Li J, Hu YH. Weekly cisplatin for the treatment of patients with ovarian cancer: A protocol for a systematic review of randomized controlled trial. *Medicine (Baltimore)*. 2019 Apr;98(14):e15001.
122. Fenlon JB, Rositch AF, Dickey BL, Kimani S, Suneja G. Gynecological radiotherapy in people living with human immunodeficiency virus: a semi-systematic literature review. *Int J Gynecol cancer Off J Int Gynecol Cancer Soc*. 2022 Mar;32(3):429–35.
123. Nara M, Ishihara S, Kitano A, Tamura N, Aruga T, Kobayashi D, et al. Does breast-conserving surgery with radiotherapy in BRCA-mutation carriers significantly increase ipsilateral breast tumor recurrence? A systematic review and meta-analysis. *Breast Cancer*. 2022 May;29(3):394– 401.
124. Faluyi O, Mackean M, Gourley C, Bryant A, Dickinson HO. Interventions for the treatment of borderline ovarian tumours. *Cochrane Database Syst Rev [Internet]*. 2010;(9). Available from:

<http://dx.doi.org/10.1002/14651858.CD007696.pub2>

125. Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynaecological cancer. *Cochrane Database Syst Rev.* 2012;(3). Available from: <http://dx.doi.org/10.1002/14651858.CD007945.pub2>
126. Hoekman EJ, Broeders EABJ, Louwe LA, Nout RA, Jansen FW, de Kroon CD. Ovarian function after ovarian transposition and additional pelvic radiotherapy: A systematic review. *Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol.* 2019 Aug;45(8):1328–40.
127. Gubbala K, Laios A, Gallos I, Pathiraja P, Haldar K, Ind T. Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis. *J Ovarian Res.* 2014;7:69.
128. Yegya-Raman N, Cao CD, Hathout L, Girda E, Richard SD, Rosenblum NG, et al. Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review. *Gynecol Oncol.* 2020 Nov;159(2):573–80.
129. Chung JH, Kang DH, Jo JK, Lee SW. Assessing the quality of randomized controlled trials published in the *Journal of Korean Medical Science* from 1986 to 2011. *J Korean Med Sci.* 2012 Sep;27(9):973–80.
130. Chundury A, Apicelli A, Dewees T, Powell M, Mutch D, Thaker P, et al. Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. *Gynecol Oncol [Internet].* 2016;6–11. Available from: <http://dx.doi.org/10.1016/j.ygyno.2016.02.005>
131. Albuquerque K, Patel M, Liotta M, Harkenrider M, Guo R, Small W, et al. Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer. *Int J Gynecol Cancer.* 2016 May 1; 26(4):655–60. Available from: <https://pubmed.ncbi.nlm.nih.gov/26825832/>
132. Yahara K, Ohguri T, Imada H, Yamaguchi S, Kawagoe T, Matsuura Y, et al. Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy. *J Radiat Res.* 2013 Mar;54(2):322–9.
133. Lazzari R, Ronchi S, Gandini S, Surgo A, Volpe S, Piperno G, et al. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a

Drug Holiday. *Int J Radiat Oncol Biol Phys* [Internet]. 2018;101(3):650–60. Available from: <https://doi.org/10.1016/j.ijrobp.2018.03.058>

134. Chang JS, Kim SW, Kim YJ, Kim JY, Park SY, Kim JH, et al. Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial. *Gynecol Oncol*. 2018 Oct;151(1):39–45.
135. Kim N, Chang JS, Kim SW, Kim GM, Lee J yun, Kim YB, et al. Involved-field radiation therapy for selected cases of recurrent ovarian cancer. 2019;30(5):1–12.
136. National Cancer Institute. CTCAE FAQ. 2010 28.10.2011; Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf.

